poster

Exposure-Response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

Pimavanserin, a selective serotonin inverse agonist/antagonist at the 5-HT2A/C receptors, is being actively studied for multiple indications. The CLARITY clinical trial program is evaluat...

10/27/2020

ENHANCE Trial: Adherence to Current Antipsychotic and Adjunctive Pimavanserin in Patients With Schizophrenia and Inadequate Response to Antipsychotic Treatment

Up to 70% of individuals with schizophrenia experience inadequate response to antipsychotic treatment potentially due to insufficient exposure due to nonadherence or to medication ineffec...

10/27/2020

Obstructive Sleep Apnea and Risk of Motor Vehicle Accidents

Introduction: Previous studies have documented increased risk of motor vehicle accidents (MVAs) in patients with obstructive sleep apnea (OSA); however, clinical practices for diagnosing/...

10/25/2020

Fremanezumab for the Prevention of Chronic Migraine in Patients with Comorbid Depression: A Pooled Analysis of Phase 3 Studies

Objective: A pooled analysis evaluated reductions in migraine and headache days among chronic migraine (CM) patients with comorbid depression (scores ≥10 on the 9-item Patient Health Ques...

10/25/2020

Task-assisted, bilateral, repetitive Transcranial Magnetic Stimulation improves verbal memory and executive function in Treatment Resistant Depression: Case Report

Background: Treatment-resistant depression (TRD) is a relatively common occurrence in clinical practice, with up to 50% to 60% of patients not achieving adequate response following antide...

10/21/2020

Prevalence of Pre-existing Conditions for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies among Patients with Treatment-Resistant Depression

BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe ph...

10/19/2020

A Telehealth Literacy Screening Tool for Patients with Psychosocial Barriers

Background: The benefits of telehealth from a social, financial, and practical sense are well established. However, there are many gaps in the literature regarding telemedicine services i...

10/19/2020

Deutetrabenazine Reduces Severe Tardive Dyskinesia Movements in a 3-year Open-Label Extension Trial

Background: There are no established treatment guidelines for tardive dyskinesia (TD) based on movement severity. The 12-week ARM-TD and AIM-TD studies in TD patients with baseline Abnorm...

10/18/2020

Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients Prescribed VMAT2 Inhibitors

Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with...

10/18/2020

Post Hoc Analyses of Treatment History on SHP465 Mixed Amphetamine Salts Extended-Release Responses in Adult Attention-Deficit/Hyperactivity Disorder

In 2 placebo-controlled studies of adults with attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release significantly reduced ADHD-Rating Sca...

10/08/2020

Tracks

MDD Insights

Schizophrenia Insights

Major Depressive Disorder

General Psychiatry

ADHD

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products